Botulinum toxin as an adjunct for severe Dupuytrens contracture treated with collagenase injections
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Even with Dupuytren's proximal interphalangeal joint (PIPJ) contractures successfully released, volar flexor muscle memory can contribute to persistent contracture. We report using botulinum toxin (BoNTA) to the flexor digitorum superficialis muscle (FDS) to reduce flexor tone during recovery. Case Description. Two Collagenase clostridium histolyticum (CCH) injections were given to a patient with a -90° (PIPJ) contracture and a -35° degree distal interphalangeal joint (DIPJ) contracture. At the first CCH injection, 20 µ total of the Botulinum toxin was placed into the FDS muscle. Manipulation occurred at one week. A second injection of CCH followed by manipulation one week later occurred at two months, but no additional BoNTA was given. The final follow-up measurements at 53 months showed a PIPJ of -30° and a DIPJ of 0°. Total active motion improved from 140° to 240°. Outcomes of any treatment for severe Dupuytren's PIPJ contractures of the little finger are unpredictable and are often considered for staged external expansion or even salvage procedures. BoNTA injections weaken flexor tone in tendon repairs and for treating hypertonic muscles after strokes. Conclusion. We hypothesized that BoNTA injection could enhance the outcomes of DC treatment by inhibiting volar flexion forces during the recovery phase. The following case illustrates that using a BoNTA injection may have helped treat a severe PIPJ contracture. BoNTA injections need further research and controlled clinical trials to discover their proper role in Dupuytren's contractures treated via CCH injections, fasciotomies, and fasciectomies.
##plugins.themes.bootstrap3.article.details##
Dupuytrens contracture, Botulinum toxin, Severe proximal interphalangeal joint contracture
2. Müller-Seubert W, Cai A, Arkudas A, Ludolph I, Fritz N, Horch RE. A Personalized Approach to Treat Advanced Stage Severely Contracted Joints in Dupuytren's Disease with a Unique Skeletal Distraction Device-Utilizing Modern Imaging Tools to Enhance Safety for the Patient. J Pers Med. 2022; 12(3):378. doi: 10.3390/jpm12030378. PMID: 35330378; PMCID: PMC8953560.
3. Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med. 2009; 361(10):968-979. doi: 10.1056/NEJMoa0810866. PMID: 19726771.
4. Barr V, Bhatia R, Hawkins P, Savage R. Intramuscular tenotomy of flexor digitorum superficialis in the distal forearm after surgical excision of dupuytren's disease. J Hand Surg Br. 2003; 28(1):37-39. doi: 10.1054/jhsb.2002.0860. PMID: 12531666.
5. De Aguiar G, Chait LA, Schultz D, et al. Chemoprotection of flexor tendon repairs using botulinum toxin. Plast Reconstr Surg. 2009; 124(1):201-209. doi: 10.1097/PRS.0b013e3181ab118c. PMID: 19568082.
6. Tüzüner S, Balci N, Ozkaynak S. Results of zone II flexor tendon repair in children younger than age 6 years: botulinum toxin type A administration eased cooperation during the rehabilitation and improved outcome. J Pediatr Orthop. 2004; 24(6):629-633. doi: 10.1097/01241398-200411000-00006. PMID: 15502560.
7. Davis SM, Chang EY. Dupuytren's contracture treated with botulinum toxin A injection. Arch Clin Cases. 2021; 7(4):63-67. doi: 10.22551/2020.29.0704.10175. PMID: 34754930; PMCID: PMC8565707..
8. Denkler K. Dupuytren PIP Joint Contractures Treated with Supplemental Botulinum Toxin to the Flexor Digitorum Sublimis Muscle, in AAHS Annual Meeting. 2019: Palm Springs.
9. Dressler D, Kopp B, Adib Saberi F. Botulinum toxin dosing in arm muscles: contextual factors. J Neural Transm (Vienna). 2021; 128(3):315-319. doi: 10.1007/s00702-021-02307-1. PMID: 33515332; PMCID: PMC7969489.
10. Simón-Pérez C, Alía-Ortega J, García-Medrano B, et al. Factors influencing recurrence and progression of Dupuytren's disease treated by Collagenase Clostridium histolitycum. Int Orthop. 2018; 42(4):859-866. doi: 10.1007/s00264-017-3690-0. PMID: 29170879.
11. David M, Smith G, Pinder R, et al. Outcomes and Early Recurrence Following Enzymatic (Collagenase) Treatment of Moderate and Severe Dupuytren Contractures. J Hand Surg Am. 2020; 45(12):1187.e1-1187.e11. doi: 10.1016/j.jhsa.2020.06.012. PMID: 32861504.
Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.
Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.
Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.